Skip to main content
. 2020 Sep;8(17):1075. doi: 10.21037/atm-20-1358a

Table 2. Clinicopathologic variables and univariate analysis of the SEER cohort of node-negative stage III gastric cancer patients.

Population No. of patients 3-year OS (%) 5-year OS (%) Univariate analysis Multivariate analysis
P value HR (95% CI) P value
Gender 0.913
   Female 76 35.0 29.8
   Male 120 36.8 30.1
Age, years 0.011 0.008
   ≤60 66 45.5 40.3 1 (Ref.)
   >60 130 30.8 26.9 1.584 (1.105–2.269)
Tumor size, cm 0.184 0.591
   ≤4 42 38.1 33.2 1 (Ref.)
   >4 120 37.5 34.8 1.006 (0.701–1.020)
   unknown 34 26.5 17.6 1.283 (0.775–2.124)
Tumor location 0.570
   Upper third 23 26.1 21.7
   Middle third 24 45.8 41.7
   Lower third 86 36.0 30.9
   >2/3 stomach 31 32.3 22.6
   Unknown 32 37.5 33.8
Lauren classification 0.120 0.216
   Intestinal 65 41.5 34.9 1 (Ref.)
   Diffuse 125 31.2 28.0 1.284 (0.896-1.840)
   unknown 6 66.7 50.0 0.671 (0.191-1.998)
ELN 0.017 0.010
   ELN ≤31 180 33.0 29.0 1 (Ref.)
   ELN >31 16 71.4 64.3 0.421 (0.184–0.964)

No., number; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; Ref, reference; ELNs, examined lymph nodes; SEER, Surveillance, Epidemiology, and End Results..